Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 24 Oct 2026, 00:28 UTC. 2 material updates are listed in the timeline. The headline in use is “Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.